Epigenetic Strategies to Boost Cancer Immunotherapies
AbstractRecently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Barrero, M.J. Epigenetic Strategies to Boost Cancer Immunotherapies. Int. J. Mol. Sci. 2017, 18, 1108.
Barrero MJ. Epigenetic Strategies to Boost Cancer Immunotherapies. International Journal of Molecular Sciences. 2017; 18(6):1108.Chicago/Turabian Style
Barrero, Maria J. 2017. "Epigenetic Strategies to Boost Cancer Immunotherapies." Int. J. Mol. Sci. 18, no. 6: 1108.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.